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is associated with a significant symptom burden. Pruritus appears to be one of 
the most prominent and disturbing symptoms. All aspects of QOL are affected in 
CTCL. Two new treatments were approved for CTCL during 2009-2012 (US), however, 
the unmet need remains high. ConClusions: This systematic review shows that 
patients with CTCL have a very poor prognosis and serious deterioration in quality 
of life. There is an urgent need for new treatments for these patients.
PCN51
EvolutioN of thE NumbEr of PatiENts trEatEd for mEtastatiC CaNCEr 
bEtwEEN 2003 aNd 2013 iN fraNCE
Flinois A, Bonnelye G, Chabernaud H
Kantar Health, Montrouge, France
objeCtives: In France, cancer incidence and mortality rates are readily avail-
able. However, less well known is the number of patients with an active disease. 
Existing prevalence data, often coming from probabilistic models, aggregate both 
cured patients having received curative treatments at an early stage and patients 
with a metastatic disease. Since the latter represent the essentials of current 
treatment needs, their recognition is necessary to evaluate crucial treatment 
resources. Methods: Conducted in France every 2 years, the ‘Cancérologie’ study 
includes an observational component requiring participating physicians to report on 
the current status and treatment of their next 15 patients (12 until 2009) seen with 
any solid or liquid cancer in the active phase. Thus, 4,430 patients were reported 
during the 2013 study (as opposed to 2,260 in 2003). Data collected were extrapo-
lated to the whole of France, using activity data from hospitals as projection coef-
ficients. Results: Between 2003 and 2013, the total number of patients treated 
for an active disease in French healthcare facilities rose from 394,000 to 521,000, 
showing an average annual increase of 2.8% which is above the estimated annual 
increase in incidence over the same period (1.7%). Meanwhile, among all patients, 
the distribution of solid tumors versus liquid tumors has remained almost identi-
cal (ratio between 90/10 and 88/12). However, the number of patients treated for a 
metastatic tumor has risen by 71% from 157,000 patients in 2003 to 269,000 in 2013 
(from 39% to 60% of total patients). Prostate, colorectal and breast cancers have been 
the strongest contributors (40%) to this increase. ConClusions: The 71% increase 
in the number of patients treated for a metastatic disease is undoubtedly the most 
significant occurrence of these past ten years in oncology. The monitoring of this 
trend, overall and by indication, is a priority.
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PrEvalENCE aNd risk faCtors of skiN CaNCEr iN mExiCo: aN 
obsErvatioNal study
Zkik A, Berdeaux G
Pierre Fabre, Boulogne Billancourt, France
objeCtives: The incidence of malignant melanoma has increased in the recent 
years and the role of ultraviolet radiation (UV) in the disease process is well estab-
lished. Indeed, epidemiological data supported that sun exposure and, more par-
ticularly sunburns during childhood are associated with a higher risk of developing 
melanoma. The present study aims at evaluating the prevalence of skin cancer and 
other skin disorders in the Mexican population and at determining the risk factors 
associated with these conditions Methods: A total of 400 dermatologists practic-
ing in the 11 most important cities of Mexico have been selected to participate in 
the study. Over a period of one week, each year from 2011 to 2014, they submitted 
questionnaires to every consulting patient. These questionnaires comprised two 
sections: one completed by the patient to gather data on risk factors and the other 
by the dermatologist to collect medical history and current diagnosis. Results: A 
total of 11841 questionnaires were completed. The mean age of the study popula-
tion was 49.3 years and respondents were predominantly women (sex ratio 2:1). The 
phototype III is the most frequently reported by study participants (about 36%) how-
ever, phototype II and IV are also cited each, by approximately 20% of individuals. 
Most study participants did not report any severe sunburns during childhood and 
almost 40% of them spent more than one hour a day in the sun. Very few patients 
have personal or family history of melanoma and less than 15% have suffered from 
non-melanoma skin cancer. At the time of the clinical examination, melanoma was 
rarely suspected (about 2% of cases). The most frequent disorder appeared to be 
basal cell carcinoma with 7% of individuals potentially affected ConClusions: 
Results from this observational study confirmed variations in the prevalence of 
the various types of skin cancer.
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objeCtives: We assessed the patient characteristics and burden of cancer hospi-
talizations amongst the most prevalent cancers in the United States. Methods: 
We conducted a cross-sectional study of the 2012 National Inpatient Sample. 
Utilizing ICD-9 codes, we identified cancers with the highest mortality rates in 
males and females. Frequencies and proportions for patient and hospital char-
acteristics were compared using bivariate statistics. Multivariable analyses were 
used to assess the outcomes associated with cancer hospitalizations while 
adjusting for confounding, including a generalized linear model for charges and 
a negative binomial model for differences in length of stay (LOS). Results: We 
estimated the incidence of cancer hospitalizations at 471,755 cases. Lung cancers 
accounted for the greatest proportion of cancer hospitalizations (27.46%), while 
liver cancers accounted for the lowest proportion (4.43%). Colorectal (median: 6 
days [Interquartile Range (IQR): 4-10]) and pancreatic (median: 6 days [IQR: 3-10]) 
cancers were associated with the longest LOS. The overall median charges for hos-
pitalization was also highest for colorectal cancer ($50,761 [IQR: $31,352-83,233]); 
however, the median charges per day were highest for prostate cancer ($23,589 
about 1.7-times more than at 3 months before death. ConClusions: If pain of can-
cer patients can be appropriately controlled according to the guideline, unnecessary 
hospitalization and ER visits will be reduced, resulting in improved quality of life of 
patients and efficient use of medical expenses; however, a number of obstacles exist 
for cancer pain control in real practice.
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objeCtives: This study explores changes in glucose lowering drug (GLD) use 
associated with cancer development and treatment among diabetic individu-
als. Methods: New GLDs users (1998-2011) living in the ECR-PHARMO catchment 
area were selected (n= 52,228). Those with a primary cancer diagnosis were con-
sidered cases (n= 3,281) and matched with eligible controls without cancer during 
follow-up (n= 12,891). Conditional logistic regression analysis was used to assess 
changes in GLD use, i.e. treatment drop and initiating insulin, for cases compared 
to controls due to specific cancer types in four time windows (3-6 and 0-3 months 
before cancer diagnosis; 0-3 and 3-6 months after cancer diagnosis). Results: 
In the 3-6 months before cancer diagnosis, gastrointestinal and pancreas cancer 
were associated with higher odds of starting with insulin (OR 3.9;95%CI 1.3-12.1 
and OR 4.9;95%CI 1.3-18.1). Colorectal (OR 3.4; 95%CI 1.4-8.4) and gastrointestinal 
(OR 13.6;95%CI 5.0-36.9) cancers were associated with increased odds of initiating 
insulin in the 3 months after cancer diagnosis. After this period, these odds were 
increased for breast (OR 4.6;95%CI 1.7-12.6) and pulmonary (OR 3.3;95%CI 1.2-9.1) 
cancers. Within all time windows odds of treatment drops were higher for patients 
with gastrointestinal cancers, while for all other cancers (except breast and pros-
tate) odds were only higher after cancer diagnosis. ConClusions: Already 3 to 6 
months before the diagnosis of gastrointestinal or pancreas cancer a higher odds 
of initiating insulin use was observed, suggesting reverse causation. Stopping GLDs 
was common after cancer diagnosis, while the diagnosis of most cancer types was 
associated with the start of insulin.
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objeCtives: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) 
has been increasing in many countries worldwide, predominantly among men in 
developed countries. OPSCC is strongly associated with human papilloma virus 
(HPV) infection, and HPV-related OPSCC has been described as an emerging epi-
demic. As HPV-related cervical cancer has been decreasing in many countries, it 
has been predicted that the number of cases of OPSCC will soon overtake cervical 
cancer. Methods: We used an administrative claims database to identify occur-
rences of diagnosis codes for cervical cancer versus diagnosis codes for cancer of 
sites known to comprise HPV-related OPSCC (oropharynx, tonsil, lingual tonsil, 
uvula, soft palate, and base of tongue)among males in the years 2005-2014. We 
calculated ratios of identified diagnoses in each calendar year. Differences in 
healthcare costs between males with OPSCC and females with cervical cancer in 
the 12 months after first diagnosis in 2013 for patients with ≥ 6 months of con-
tinuous enrollment were estimated. Results: Males comprised 73% of all OPSCC 
diagnoses in 2005 and 79% in 2014. The ratio of cervical cancer diagnoses versus 
OPSCC was 1.61 in 2005, with an inversion to 0.98 by 2014. Ratios decreased steadily 
from 2005 to 2014. A total of 3,286 OPSCC diagnoses in 2005 and 7,694 diagnoses in 
2014 were identified among males, with 5,290 and 7,572 for cervical cancer, respec-
tively. For males with OPSCC, overall costs in the year after first 2013 diagnosis 
was $56,974 for patients aged 50-54 and $58,900 for patients aged 55-59. Females 
with cervical cancer averaged $42,987 and $46,513, respectively. ConClusions: 
Trends toward higher relative prevalence of HPV-related OPSCC versus HPV-related 
cervical cancer were confirmed in this population of US patients with employer-
sponsored insurance. The rising incidence and substantial costs associated with 
OPSCC warrant greater attention to prevention efforts through vaccination against 
HPV, particularly among men.
PCN50
systEmatiC rEviEw of burdEN of CutaNEous t-CEll lymPhoma
Aggarwal S1, Topaloglu H1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, 
USA
objeCtives: Cutaneous T-Cell Lymphoma (CTCL) is a rare and serious cancer with 
significant deterioration in patient quality of life. The objective of this research was 
to conduct a systematic review of epidemiology and the burden of CTCL. Methods: 
A systematic literature search for epidemiology and the burden of disease studies 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar and 
Cochrane. Data was collected for the study type, methods, country and key findings. 
Extracted study data included: CTCL incidence, complications, mortality, available 
treatment options, as well as healthcare resource utilization and medical costs 
associated with CTCL. Critical analyses of study quality and data gaps were analyzed 
at the country level. Results: A total of 50 studies were identified based on the 
keywords. Of these, 14 studies met the inclusion criteria. Studies indicate that CTCL 
is a group of disorders characterized by localization of neoplastic T lymphocytes 
to the skin. Annual overall incidence of CTCL was 6.4 per million persons between 
1973 and 2002. CTCLs accounted for 71%, with Mycosis fungoides (MF) and Sézary 
syndrome (SS) representing the most common sub-types (54 % of all CTCLs). CTCL 
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words. Of these, 32 studies met the inclusion criteria. Studies indicate that pancreatic 
cancer has an extremely poor prognosis: for all stages combined, the 1- and 5-year 
relative survival rates are 25% and 6%, respectively. Pancreatic cancer is the fourth 
most common cause of cancer-related deaths in the United States and the eighth 
worldwide. More than 50% of patients come to clinical attention with metastatic 
disease, and an additional 30%–40% present with locally advanced tumors. Current 
treatments include surgery and palliative chemotherapy such as gemicitabine and 
gemcitabine/erlotinib combination. Recently nab-paxclitacel was approved based on 
a 1.8 month improvement in the overall survival. ConClusions: This systematic 
review shows that patients with pancreatic cancer have a very low survival rate. There 
is an urgent need for new treatments for these patients.
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objeCtives: This study evaluated the effect of metformin use on survival in 
pancreatic cancer patients with curative resection and type 2 diabetes mellitus 
(T2DM). Methods: A total of 28,862 were initially identified from Korea Center 
Cancer Registry (KCCR) who had diagnostic code for pancreatic carcinoma between 
1 January 2005 and 31 December 2011. Among them, those with curative resec-
tion or T2DM and aged over 40 years were included. Subjects were classified as 
metformin user group if they were prescribed metformin around the time of diag-
nosis for pancreatic cancer. Medication possession ratio (MPR) of more than 80% 
was considered as acceptable adherence. Survival from pancreatic carcinoma was 
identified from the linkage of National Population Registry of the Korea National 
Statistical Office with KCCR through December 31, 2013. Several sensitivity analyses 
were performed to examine the effect of immortal time bias, and confounding vari-
ables. Results: The study included 764 subjects with T2D and pancreatic cancer 
with curative resection, 530 of which were exposed to metformin. In multivariable 
analysis, the adjusted risk for pancreatic cancer specific mortality of metformin 
user was significantly lower than that of metformin non-user (hazard ratio, 0.73; 
95% CI, 0.61 to 0.87; P < 0.001). The adjusted risk for mortality was also significantly 
lower in MPR of more than 80% compared with that of MPR of less than 80% (HR, 
0.60, 95% CI: 0.47-0.76, p-value< 0.001). In addition, similar results were found from 
a serial of seneitivity analysis. ConClusions: Metformin use in diabetic patients 
with pancreatic cancer is associated with improved survival. This may provide a 
rationale for further prospective study of the use of metformin as an adjunct to the 
standard of care in the treatment of pancreatic cancer.
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statiNs usE aNd thE risk of hEmatologiCal aNd NoN-hEmatologiCal 
maligNaNCiEs: a mEta-aNalysis of 53 obsErvatioNal studiEs
Bhutani MK, Rai MK, Kaneria J, Goyal R, Kumar R, Raute L
Tata Consultancy Services, Mumbai, India
objeCtives: Statins are frequently prescribed drugs worldwide, used for the 
management and prevention of coronary artery diseases. In contrast to early 
concerns over carcinogenicity of statins, recent evidences suggest that statins 
may have chemo-preventive potential against variety of cancers. We performed a 
detailed meta-analysis of observation studies to quantify the association between 
statins and risk of cancers. Methods: A comprehensive search was performed in 
EMBASE®/Cochrane/Pubmed to retrieve studies investigating association of statins 
and hematological and non-hematological cancers (prostate, breast, lung, and colo-
rectal). The studies were screened and abstracted by two independent reviewers. 
The studies were assessed for heterogeneity and pooled relative risks and 95% CIs 
were calculated using fixed effect and random effect models. Results: Of the 
4500 retrieved articles, 53 observational studies (27 case control and 26 cohort) 
contributed to analysis. The use of statins had modest chemo-protective potential 
against non-hematological cancers (prostate, breast, lung, and colorectal taken alto-
gether). However, the association did not reach statistical significance (RR= 0.93; 
95% CI, 0.87 to 1.0, p= 0.09). There was no significant association between statins 
use and risk of prostate (RR= 0.93; 95% CI, 0.79 to 1.09, p= 0.16), breast (RR= 0.97; 95% 
CI, 0.91 to 1.03, p= 0.3), lung (RR= 0.90; 95% CI, 0.75 to 1.08, p= 0.25), and colorectal 
cancer (RR= 0.94; 95% CI, 0.88 to 1.0, p= 0.06). In contrast, statins use was associated 
with significant reduction in risk of hematological malignancies (RR= 0.82; 95% CI, 
0.67 to 0.99, p= 0.04). Following the statins use, risk of non-hodgkin’s lymphoma 
(RR= 0.69; 95% CI, 0.49 to 0.96, p= 0.03) was reduced whereas no association was 
observed with lymphoma (RR= 0.99; 95% CI, 0.37 to 2.69, p= 0.99). ConClusions: 
Our meta-analysis results demonstrated that statins were associated with a mod-
est reduction in risk of non-hematological cancers, when taken for management 
of hypercholesterolemia. On the contrary, statins demonstrated chemo-protective 
potential against risk of hematological malignancies.
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adjustiNg for Cross-ovEr iN oNCology trials: aPProaChEs takEN to 
suPPort drug rEimbursEmENt iN australia
O’Leary BA1, Gordois AL1, McElroy H2
1Covance Market Access Services Inc., Sydney, Australia, 2Covance (Asia) Pte Ltd, Singapore, 
Singapore
objeCtives: Trials of new oncology treatments often allow patients to crossover 
from control to experimental treatment either at disease progression or a specific 
time point. If crossover occurs after progression, progression free survival is largely 
unaffected; however overall survival (OS) is confounded in the control arm. Patients 
switching treatments often have different prognoses, resulting in a biased estimated 
OS difference. Advanced statistical methods to adjust for crossover include Rank 
Preserving Structural Failure Time (RPSFT) models, Inverse Probability of Censoring 
[IQR: $13,220-38,966]). Adjusting for patient and facility characteristics, total 
charges for lung ($ 2396, p= 0.03), colorectal ($10,844, p< 0.0001), and pancreatic 
cancers ($ 7504, p< 0.0001) were significantly higher than liver cancers. Significant 
predictors of LOS included race/ethnicity (compared to whites, 15% longer for 
blacks (IRR= 1.15, 95% CI: 1.13-1.17 ) and 4% longer for Hispanics (IRR= 1.04, 95% 
CI: 1.02-1.06) and hospital location (compared to rural hospitals, 12% longer for 
non-teaching urban (IRR= 1.12, 95% CI: 1.10-1.14) and 15% longer for teaching urban 
(IRR= 1.15, 95% CI: 1.13-1.17). ConClusions: We found significant differences in 
proportion of hospitalizations, LOS, and charges between cancer types, moderated 
by patient and facility characteristics. Of the cancer sites considered, liver cancers 
had the lowest incidence of hospitalization, shortest LOS, and lowest total charges.
PCN54
assEssmENt of rENal fuNCtioN amoNg PatiENts with boNE 
mEtastasEs from solid tumors
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objeCtives: To examine the change in renal function among patients with bone 
metastases (BM) from solid tumors (ST) Methods: A retrospective cohort study 
was conducted using OSCER (Oncology Services Comprehensive Electronic Records) 
database, containing electronic medical records from > 50 outpatient oncology/
hematology practice groups in the US. The study sample included adults (age > = 
18 years) diagnosed with a single ST and BM between 01/01/2012 through 09/30/2013. 
Changes in renal function from baseline (6 months prior to the BM diagnosis) over 
the follow-up period were assessed. The outcomes of interest include clinically-
meaningful increase in serum creatinine (SeCr) [defined as 0.5 mg/dL increase 
in patients with normal baseline levels (< 1.4 mg/dL), and 1.0 mg/dL increase in 
those with elevated baseline levels (≥ 1.4 mg/dL)], estimated glomerular filtration 
rate (eGFR), and chronic kidney disease (CKD) stage (1: eGFR> 90 to 5: eGFR< 15). 
Descriptive analysis was conducted to examine baseline patient characteristics 
and change in renal function. Results: A total of 6,380 patients met the eligibility 
criteria; majority of them were female (52%), Caucasian (70%), with mean age of 67 
years (Standard Deviation [SD]: 12), mean SeCr of 1.0 (SD: 0.5), and mean eGFR of 77 
(SD: 23) at baseline. During a median follow-up of 191 days after BM diagnosis, an 
average 11-point (SD: 17) reduction (relative reduction: 13%) in eGFR from baseline 
was observed. Clinically-meaningful increases in SeCr were observed in 10.8% of 
the patients overall; among 7.2% patients from elevated (n= 706) and 11.3% from 
normal (n= 5,674) baseline SeCr levels. Increases in CKD stage from baseline levels 
were observed in 36% of the patients. ConClusions: Worsened renal function was 
observed among patients with ST and BM. Given the use of bone targeting agents 
in this patient population, future analysis is needed to understand the impact of 
those agents, such as zoledronic acid, on renal function.
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EPidEmiology aNd trEatmENt of soft tissuE sarComa iN thE Eu5
Robinson D, Nersesyan K, Pomerantz D
Kantar Health, Horsham, PA, USA
objeCtives: Explore the epidemiology and treatment of soft tissue sarcoma (STS) 
in EU5. Methods: Epidemiology of STS was derived from the Kantar Health (KH) 
CancerMPact database, sources for which include country specific cancer regis-
tries, published scientific studies and proprietary physician surveys conducted 
in March 2015 comprising 76 doctors seeing an average of 3,210 STS patients per 
month. Country specific age and gender incidence rates were applied to country 
population data to determine number of newly diagnosed STS patients. Annual 
non-metastatic and metastatic progression rates and annual non-metastatic and 
metastatic survival rates are used to calculate total number of surviving patients 
up to 10 years after diagnosis. Treatment data was determined from the physi-
cian surveys and was country specific. Results: Incidence of STS ranged from 
3.1 – 4.1 per 100K . Among all incident STS patients, 74% were non metastatic and 
16% were metastatic. Surgery/Drug/Radiation rates were, respectively, 43%/37%/19% 
in France, 52%/42%/22% in Germany, 49%/31%/27% in Italy, 41%/34%/29% in Spain 
and 45%/28%/27% in the UK. Among metastatic patients, 41% to 44% received a 
first line drug. There was wide variation in the % of first line that received second 
line (range 35% - 58%) and second line who received third (17% - 30%). Among 
first line drug treated doxorubicin plus ifosfamide was the preferred regimen in 
France, Germany and Spain whereas doxorubicin monotherapy was preferred in UK. 
Trabectedin and pazopanib were used relatively frequently as second or third line 
treatments. ConClusions: This study confirms the rarity of soft tissue sarcoma in 
EU5. Doxorubicin plus ifosfamide is the most commonly used treatment in first line 
across EU5, trabectedin and pazopanib tend to be the most utilized treatments in 
second and third line. Variance to the trend is apparent in France and Spain second 
line and in France and UK third line.
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objeCtives: Pancreatic cancer is considered one of the toughest cancers to treat, with 
extremely poor prognosis. The objective of this research was to conduct a systematic 
review of epidemiology and the burden of pancreatic cancer. Methods: A systematic 
literature search for epidemiology and the burden of disease studies was undertaken 
for the databases Pubmed, Embase, Biosis, Google Scholar and Cochrane. Data was 
collected for the study type, methods, country and key findings. Extracted study data 
included pancreatic cancer incidence, complications, mortality, available treatment 
options, as well as healthcare resource utilization and medical costs associated with 
pancreatic cancer. Critical analyses of study quality and data gaps were analyzed at 
the country level. Results: A total of 328 studies were identified based on the key-
